Mechanisms and therapeutic implications of hypermutation in gliomas-Reference-Cited by-同舟云学术

Mechanisms and therapeutic implications of hypermutation in gliomas

Published:2020-04-15 Issue:7804 Volume:580 Page:517-523
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Touat Mehdi,Li Yvonne Y.,Boynton Adam N.,Spurr Liam F.,Iorgulescu J. Bryan^ORCID,Bohrson Craig L.,Cortes-Ciriano Isidro,Birzu Cristina,Geduldig Jack E.,Pelton Kristine,Lim-Fat Mary Jane^ORCID,Pal Sangita,Ferrer-Luna Ruben,Ramkissoon Shakti H.,Dubois Frank,Bellamy Charlotte,Currimjee Naomi,Bonardi Juliana,Qian Kenin^ORCID,Ho Patricia^ORCID,Malinowski Seth,Taquet Leon,Jones Robert E.,Shetty Aniket,Chow Kin-Hoe,Sharaf Radwa,Pavlick Dean,Albacker Lee A.,Younan Nadia,Baldini Capucine,Verreault Maïté,Giry Marine,Guillerm Erell,Ammari Samy,Beuvon Frédéric,Mokhtari Karima,Alentorn Agusti,Dehais Caroline,Houillier Caroline,Laigle-Donadey Florence,Psimaras Dimitri,Lee Eudocia Q.,Nayak Lakshmi,McFaline-Figueroa J. Ricardo,Carpentier Alexandre,Cornu Philippe,Capelle Laurent,Mathon Bertrand,Barnholtz-Sloan Jill S.^ORCID,Chakravarti Arnab,Bi Wenya Linda,Chiocca E. Antonio,Fehnel Katie Pricola,Alexandrescu Sanda,Chi Susan N.,Haas-Kogan Daphne,Batchelor Tracy T.,Frampton Garrett M.,Alexander Brian M.,Huang Raymond Y.,Ligon Azra H.,Coulet Florence,Delattre Jean-Yves,Hoang-Xuan Khê,Meredith David M.,Santagata Sandro^ORCID,Duval Alex^ORCID,Sanson Marc,Cherniack Andrew D.^ORCID,Wen Patrick Y.,Reardon David A.,Marabelle Aurélien,Park Peter J.^ORCID,Idbaih Ahmed,Beroukhim Rameen^ORCID,Bandopadhayay Pratiti,Bielle Franck,Ligon Keith L.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41586-020-2209-9.pdf

Reference65 articles.

1. Hunter, C. et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res. 66, 3987–3991 (2006).

2. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061–1068 (2008).

3. Johnson, B. E. et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343, 189–193 (2014).

4. Wang, J. et al. Clonal evolution of glioblastoma under therapy. Nat. Genet. 48, 768–776 (2016).

5. Barthel, F. P. et al. Longitudinal molecular trajectories of diffuse glioma in adults. Nature 576, 112–120 (2019).

Cited by 366 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic review of immunotherapy in high-grade glioma: learning from the past to shape future perspectives;Neurological Sciences;2024-02-03

2. Glioblastoma vaccines: past, present, and opportunities;eBioMedicine;2024-02

3. Rise of oligodendroglioma hypermutator phenotype from a subclone harboring TP53 mutation after TMZ treatment;Brain Tumor Pathology;2024-01-31

4. Aberrant MET Receptor Tyrosine Kinase Signaling in Glioblastoma: Targeted Therapy and Future Directions;Cells;2024-01-25

5. Resistance patterns in drug-adapted cancer cell lines reflect complex evolution in clinical tumors;2024-01-23